Society of the Novel Action of Sirolimus

JASMINSociety of the Novel Action of Sirolimus

JASMIN Society of the Novel Action of Sirolimus: Japanese Association of
Sirolimus Medical Investigation Network― JASMIN Society ―About JASMIN Society

Established as a venue for information exchange,
JASMIN Society pursues the dual approaches of (1) basic research and (2) clinical research into the discovery and application of the novel actions of sirolimus.

Notices

April 1, 2022 / Academic MeetingThe JASMIN Society 2021 Proceedings release Lecture and Presentation Booklet.
May 26, 2021 / Academic MeetingInformation on the 2nd Meeting of the Society of the Novel Action of Sirolimus
October 6, 2020 / Academic MeetingRequest for Pre-Registration for the Meeting of the Society of the Novel Action of Sirolimus
October 3, 2020 / Academic MeetingInformation on the 1st Meeting of the Society of the Novel Action of Sirolimus

Cutting edge

January 29, 2021 / Cutting edgesProlonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
December 16, 2020 / Cutting edgesIs sirolimus effective to sarcoidosis?
December 16, 2020 / Cutting edgesSirolimus as a promising candidate for COVID19

Diseases Studied

Complex vascular abnormality (CVA)
Fibrodysplasia ossificans progressiva (FOP studies)
Focal cortical dysplasia (FCD) type II epilepsy
Pendred syndrome/DFNB4
Idiopathic multicentric Castleman disease (iMCD)
Primary immunodeficiency syndrome (PID)
Neurofibromatosis type I (NF1)
Lymphangioleiomyomatosis (LAM)
Tuberous sclerosis complex (TSC)

About Sirolimus

eveloped for use in the prevention of organ transplant rejection, sirolimus is an antibiotic that inhibits mTOR, a kinase involved in cell division and metabolism. Sirolimus has been approved in 55 countries as a post-kidney transplant drug and has been used for over 20 years.

Sirolimus was isolated from soil bacteria on the Polynesian island of Rapa Nui (also known as Easter Island), from which the compound takes its alternate name "rapamycin." It is an immunosuppressive drug that suppresses the action of lymphocytes (a type of immune cell), which cause the rejection of transplanted tissues and organs, and acts as a serine/threonine kinase inhibitor.
Sirolimus has been found to be effective against a variety of tumors and continues to be a topic of research.

Detailed Information

Japan Intractable Diseases Information Center Japan Intractable Diseases Research Foundation Japan Agency for Medical Research and Development